(Circulation. 1999;100:690-692.)
© 1999 American Heart Association, Inc.
Brief Rapid Communication |
Amiodarone Protects Cardiac Myocytes Against Oxidative Injury by its Free Radical Scavenging Action
From the Research Institute of Angiocardiology and Cardiovascular Clinic, Kyushu University School of Medicine (T.I., H.T., S.K., A.T.), and Department of Biophysics, Faculty of Pharmaceutical Sciences, Kyushu University (H.U.), Fukuoka, Japan
Correspondence to Hiroyuki Tsutsui, MD, PhD, Research Institute of Angiocardiology and Cardiovascular Clinic, Kyushu University School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan. E-mail prehiro{at}cardiol.med.kyushu-u.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Oxidative stress plays an important role in the pathophysiology of ischemic heart disease and heart failure, and antioxidants might be beneficial in the treatment of these patients. This study was performed to determine the scavenging effects of amiodarone on oxygen free radicals and its protective effects against oxygen radical-mediated injury in cardiac myocytes.
Methods and Results—The formation of the radical spin adduct with hydroxy radical (·OH) in the presence of H2O2 (10 mmol/L) and Fe3+-nitrilotriacetate (20 µmol/L) was monitored by electron paramagnetic resonance spectroscopy combined with a spin trapping agent, 5,5-dimethyl pyrroline-N-oxide (DMPO). Amiodarone decreased the intensity of the DMPO-OH signals in a dose-dependent manner (0.1 to 100 µmol/L), whereas other antiarrhythmia drugs such as disopyramide and atenolol had no such effects. Furthermore, amiodarone (10 µmol/L) protected intact adult canine cardiac myocytes against ·OH-mediated myocyte injury, as assessed by the degree of morphological change from rod shape to the irreversible hypercontracture state during the exposure of cells to H2O2 and Fe3+ in vitro.
Conclusions—Amiodarone can protect cardiac myocytes against oxidative stress-mediated injury by directly scavenging oxygen free radicals. Antioxidant action of amiodarone might potentially contribute to the beneficial effects of this drug in the treatment of patients with ischemic heart disease and congestive heart failure.
Key Words: myocytes • free radicals • antiarrhythmia agents • spectroscopy
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Recent studies have demonstrated that amiodarone improves the clinical status and left ventricular function in patients with heart failure (HF).1 2 It is noteworthy that amiodarone may reduce total mortality and arrhythmic/sudden death in HF patients or survivors of myocardial infarction.3 This is in clear contrast to other antiarrhythmia drugs, which have actually increased mortality, as shown by carefully evaluated large randomized trials of high risk patients.3 4 These significant clinical benefits have made amiodarone the antiarrhythmic agent of choice in the current treatment of HF patients.5
Oxidative stress has been shown to play an important role in the pathophysiology of ischemic heart disease6 and recently in congestive HF.7 8 Oxygen radicals can produce deleterious effects on the myocardium, including contractile dysfunction and structural damage.9 In addition, they can damage vascular endothelial cells. Therefore, oxygen radical-mediated myocardial injury may be involved in the initiation and progression of HF. In addition, it has been suggested that the beneficial effects of carvedilol on HF may be attributable, at least in part, to its antioxidant action.10 11 Recent studies have suggested that amiodarone exhibits inhibitory effects against oxygen radical-mediated lipid peroxidation of rat liver mitochondria.12 Antioxidant activity, if present, may provide additional cardiovascular effects of this drug. However, to our knowledge, no study has examined the radical scavenging action of amiodarone and its protective effects against oxygen radical-mediated cardiac injury in myocytes.
The present study was undertaken to determine whether amiodarone is a free radical scavenger by using in vitro electron paramagnetic resonance (EPR) spectroscopy with spin trap. We also sought to determine whether it is protective against exogenously generated oxygen radical-mediated injury in isolated intact cardiac myocytes. We used isolated myocyte preparations to avoid the confounding systemic effects of amiodarone and to examine its direct effects on myocytes.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Direct EPR Measurements of Oxygen Radicals
The procedures for EPR with spin trapping agents to directly detect oxygen free radicals were described previously by Mak et al.13 Briefly, hydroxy free radical (·OH) was generated from H2O2 (10 mmol/L) in the presence of an iron redox chelate, Fe3+-nitrilotriacetate (NTA; 20 µmol/L).9 A spin trap, 5,5'-dimethyl-1-pyroline-N-oxide (DMPO; 80 mmol/L), was reacted with ·OH in the presence or absence of amiodarone or other test drugs. The formation of the radical spin adduct, DMPO-OH, was monitored with a spectrometer (JES-RE-1X, JEOL Ltd) operating at X-band (9.43 GHz) and a microwave power of 5.0 mW. A range of external magnetic field of 20 mT was swept at a scan rate of 10 mT/min. The amplitude of EPR spin signal, which is proportional to the free radical formation, was used to estimate the scavenging effects of drugs. Quantification of the DMPO signal intensity was performed by comparing the amplitude of the observed signal to a standard Mn2+/MgO marker.
·OH-Mediated Cardiac Myocyte Injury
Cardiac myocytes were isolated from the canine left
ventricular free wall as described
previously.14 Isolated cells were placed in a chamber on
the stage of an inverted microscope (Olympus) and superfused with the
oxygenated Krebs buffer (pH 7.4, 35°C).
Amiodarone and other test drugs were preincubated for 15
minutes before the addition of
H2O2 (10
mmol/L)-Fe3+-NTA (20 µmoll/L). The image
of the cell was acquisited via CCD camera and recorded continuously
on a video tape during the experiment. The length of rod shaped cells
(15 to 30 cells per experiment), determined along its longitudinal
axis, was measured.
Statistical Analysis
Data are expressed as mean±SEM. An ANOVA with repeated measures
was used to compare the time-dependent changes of cell length after the
exposure of myocytes to ·OH between control and HF. Differences
were considered statistically significant at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
·OH Scavenging Action of Amiodarone
The formation of the spin adduct DMPO-OH was evidenced by the appearance of 1:2:2:1 EPR hyperfine splitting pattern characteristic for ·OH (Figure 1A
). As expected,
catalase (H2O2 scavenger; 5
U/mL) or mannitol (·OH scavenger; 100 mmol/L) showed significant
attenuation of EPR spin signals, indicating that EPR signals indeed
originated from ·OH. Amiodarone inhibited the DMPO-OH
signal height in a concentration-dependent manner (Figure 1B).
Under the same conditions, disopyramide (10 µmol/L)
and atenolol (10 µmol/L) had no such effects on the EPR signals.
These results indicate that amiodarone is capable of directly
scavenging ·OH generated from the
H2O2+Fe3+-NTA
system.
|
P<0.01 for
difference from control value (no amiodarone).
#P<0.05 for difference from 0.1 µmol/L of
amiodarone.
Protective Effects of Amiodarone against
·OH-Mediated Cardiac Myocyte Injury
Myocytes had no morphological changes in the control buffer
without H2O2 or
Fe3+-NTA during the time of the study for 25
minutes. The addition of either
H2O2 or
Fe3+-NTA did not induce any morphological
changes. The combined addition of
H2O2 and
Fe3+-NTA induced myocyte hypercontracture after
10 minutes of exposure; thereafter, myocytes shortened to a square
hypercontracture state after 20 minutes (Figure 2), which was irreversible even after
replacing the bathing media into normal buffer (n=8 preparations).
·OH-induced hypercontracture was significantly inhibited in the
presence of catalase (50 U/mL) or mannitol (100 mmol/L),
indicating that hypercontracture was indeed mediated by the generation
of ·OH radical.
|
) for 15 minutes before exposure to
H2O2+Fe3+-NTA. Each preparation
consisted of 15 to 30 myocytes. Amiodarone significantly
(P<0.05) inhibited ·OH-mediated myocyte
hypercontracture. *P<0.05 in comparison between vehicle
and amiodarone by ANOVA.
Amiodarone (10 µmol/L; n=8 preparations) exerted
significant (P<0.05) protection against the loss of
viability (Figure 2
). In contrast, disopyramide
(10 µmol/L) and atenolol (10 µmol/L) had no such
effects.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study indicated, for the first time, that amiodarone could directly quench ·OH radical in vitro and exert a protective effect against ·OH radical-mediated cardiac myocyte injury. These effects were not observed in other antiarrhythmia drugs such as disopyramide and atenolol.
EPR studies demonstrated that the signal height of DMPO-OH, proportional to the amount of ·OH, was decreased in the presence of amiodarone, which indicated that this compound effectively suppressed the formation of the DMPO-OH adduct. Therefore, amiodarone has an ability to directly scavenge ·OH radicals. This is in accordance with the recent observation that this drug can inhibit lipid peroxidation in rat liver mitochondrial membranes challenged by an iron-dependent oxygen radical generating system.12
The exposure of isolated adult cardiac myocytes to exogenously
generated ·OH radicals resulted in time-dependent morphological
changes, as evidenced by the irreversible hypercontracture, which has
been known as an in vitro model of oxidant stress-induced myocyte
injury.9 Amiodarone showed a partial but
significant inhibition of oxygen radical-mediated hypercontracture in
cardiac myocytes. The protective effects of amiodarone could
result from its direct scavenging action on ·OH before reaching
the cellular sites of injury because cell damage was prevented at a
concentration similar to that for inhibition of DMPO-OH adduct
formation. Further, even though a direct comparison may not be
appropriate, the magnitude of the effects of amiodarone on
cellular damage shown in Figure 2 is commensurate with that on
·OH formation shown in Figure 1. However,
amiodarone may also interact with the membrane lipids and
interrupt the free radical chain reactions, which could contribute to
its protection against ·OH-induced lipid peroxidation and
cellular injury. The present study did not intend to identify the
structural requirements for the antioxidant capacity of
amiodarone, and thus the mechanisms by which it scavenges
oxygen radicals remain to be clarified.
The effective concentration of amiodarone for cardioprotective effects in this study (10 µmol/L) appears to be several times higher than its plasma concentration in patients given this drug (0.5 to 2.5 µg/mL or 0.7 to 3.5 µmol/L).15 However, this drug is a highly lipophilic compound,16 suggesting a high affinity of this drug to the plasma membranes.17 Therefore, it is conceivable that an effective tissue concentration level of amiodarone for exerting the cardioprotective action may be attainable when administered in vivo.
We have shown that amiodarone is an antioxidant and is unique among antiarrhythmia drugs in this respect. Recently, oxidative stress has been implicated in the progression of HF as evidenced by increased oxygen radical generation in failing hearts.7 8 Vitamin E, an endogenous antioxidant, has been shown to preserve myocardial structure and function in an animal model of HF.18 We thus speculate that antioxidant effects of amiodarone might play an important role in the reversibility or prevention of HF. However, the clinical significance of antioxidant action of amiodarone has not been established in this study.
In conclusion, amiodarone protects cardiac myocytes against oxidative stress-mediated injury by scavenging oxygen free radicals. In view of increasing evidence that oxygen radical-mediated myocardial injury is implicated in the pathogenesis of HF,7 8 the antioxidant effects of amiodarone, along with its antiarrhythmic effects, would potentially increase its therapeutic value in the treatment of patients with HF.
|
Acknowledgments |
|---|
Supported in part by grants from the Ministry of Education, Science, and Culture (Nos. 07266220, 08258221, and 09670724).
Received May 20, 1999; revision received June 21, 1999; accepted June 28, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
-
Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis
HD, Deedwania PC, Massie BM, Colling C, Lazzeri D. Amiodarone
in patients with congestive heart failure and asymptomatic
ventricular arrhythmia. Survival Trial of
Antiarrhythmic Therapy in Congestive Heart Failure. N Engl
J Med. 1995;333:77–82.
[Abstract/Free Full Text]
-
Massie BM, Fisher SG, Radford M, Deedwania PC, Singh
BN, Fletcher RD, Singh SN. Effect of amiodarone on clinical
status and left ventricular function in patients with
congestive heart failure. Circulation. 1996;93:2128–2134.
[Abstract/Free Full Text]
-
The Cardiac Arrhythmia Suppression Trial
(CAST) Investigators. Effect of encainide and flecainide on mortality
in infarction. N Engl J Med. 1989;321:406–412.[Abstract]
-
Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil
DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP, The SWORD
Investigators. Effect of d-sotalol on mortality in patients with left
ventricular dysfunction after recent and remote myocardial
infarction. Lancet. 1996;348:7–12.[Medline]
[Order article via Infotrieve]
-
Stevenson WG. Mechanisms and management of
arrhythmias in heart failure. Curr Opin Cardiol. 1995;10:274–281.[Medline]
[Order article via Infotrieve]
-
Bolli R. Mechanism of myocardial "stunning."
Circulation. 1990;82:723–738.
[Abstract/Free Full Text]
-
Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free
radicals and congestive heart failure. Br Heart J. 1991;65:245–248.
[Abstract/Free Full Text]
-
Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J,
Tedgui A. Elevated levels of 8-iso-prostaglandin F2
in pericardial fluid of patients with heart failure. A potential role
for in vivo oxidant stress in ventricular dilatation
progression to heart failure. Circulation. 1998;97:1536–1539.[Abstract/Free Full Text]
-
Josephson RA, Silverman HS, Lakatta EG, Stern MD,
Zweier JL. Study of the mechanisms of hydrogen peroxide and hydroxyl
free radical-induced cellular injury and calcium overload in cardiac
myocytes. J Biol Chem. 1991;266:2354–2361.
[Abstract/Free Full Text]
-
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB,
Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure. N Engl
J Med. 1996;334:1349–1355.
[Abstract/Free Full Text]
-
Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R,
Gu JL, Lysko KA, Davis LL, Feuerstein G. Carvedilol, a new vasodilator
and beta adrenoceptor antagonist, is an antioxidant and
free radical scavenger. J Pharm Exp Ther. 1992;263:92–98.
[Abstract/Free Full Text]
-
Ribeiro SM, Campello AP, Nascimento AJ, Kluppel ML.
Effect of amiodarone (AMD) on the antioxidant enzymes, lipid
peroxidation and mitochondrial metabolism. Cell
Biochem Funct. 1997;15:145–152.[Medline]
[Order article via Infotrieve]
-
Mak I, Arroyo C, Weglicki W. Inhibition of sarcolemmal
carbon-centered free radical formation by propranolol.
Circ Res. 1989;65:1151–1156.
[Abstract/Free Full Text]
-
Igarashi-Saito K, Tsutsui H, Yamamoto S, Takahashi M,
Kinugawa S, Tagawa H, Usui M, Yamamoto M, Egashira K, Takeshita A. Role
of SR Ca2+-ATPase in contractile dysfunction of
myocytes in tachycardia-induced heart failure.
Am J Physiol. 1998;275:H31–H40.
-
Heger JJ, Prystowsky EN, Zipes DP. Relationship between
amiodarone dosage, drug concentrations and adverse side
effects. Am Heart J. 1983;106:931–935.[Medline]
[Order article via Infotrieve]
-
Jendrasiak GL, McIntosh TJ, Ribeiro A, Porter RS.
Amiodarone-liposome interaction: a multi-nuclear NMR and X-ray
diffraction study. Biochim Biophys Acta. 1990;1024:19–31.[Medline]
[Order article via Infotrieve]
-
Trumbore M, Chester DW, Moring J, Rhodes D, Herbette
LG. Structure and location of amiodarone in a membrane bilayer
as determined by molecular mechanics and quantitative x-ray
diffraction. Biophys J. 1988;54:535–543.
[Abstract/Free Full Text]
-
Dhalla AK, Hill MF, Singal PK. Role of oxidative stress
in transition of hypertrophy to heart failure. J
Am Coll Cardiol. 1996;28:506–514.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  S. Wagner, T. Seidler, E. Picht, L. S Maier, V. Kazanski, N. Teucher, W. Schillinger, B. Pieske, G. Isenberg, G. Hasenfuss, et al. Na+-Ca2+ exchanger overexpression predisposes to reactive oxygen species-induced injury Cardiovasc Res, November 1, 2003; 60(2): 404 - 412. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ashrafian and P. Davey Is Amiodarone an Underrecognized Cause of Acute Respiratory Failure in the ICU? Chest, July 1, 2001; 120(1): 275 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ukai, C.-P. Cheng, H. Tachibana, A. Igawa, Z.-S. Zhang, H.-J. Cheng, and W. C. Little Allopurinol Enhances the Contractile Response to Dobutamine and Exercise in Dogs With Pacing-Induced Heart Failure Circulation, February 6, 2001; 103(5): 750 - 755. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tsutsui, T. Ide, S. Hayashidani, N. Suematsu, H. Utsumi, R. Nakamura, K. Egashira, and A. Takeshita Greater susceptibility of failing cardiac myocytes to oxygen free radical-mediated injury Cardiovasc Res, January 1, 2001; 49(1): 103 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Filippatos, B. D. Uhal, H. Tsutsui, T. Ide, S. Kinugawa, A. Takeshita, and H. Utsumi Effects of Amiodarone on Heart Cells Response Circulation, November 14, 2000; 102 (20): e170 - e170. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ide, H. Tsutsui, S. Kinugawa, N. Suematsu, S. Hayashidani, K. Ichikawa, H. Utsumi, Y. Machida, K. Egashira, and A. Takeshita Direct Evidence for Increased Hydroxyl Radicals Originating From Superoxide in the Failing Myocardium Circ. Res., February 4, 2000; 86(2): 152 - 157. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||